Table 5.
Anti-cancer drug resistance-associated lncRNAs in CML
| lncRNA | Sample source | Functional involvement and mechanism of action lncRNAs in drug resistance | Approaches for lncRNAs characterization in drug resistance | References | ||
|---|---|---|---|---|---|---|
| Cell proliferation/cytotoxicity, cell viability assay | Manipulation approaches for lncRNAs | Mechanism characterization approach | ||||
| UCA1 | Imatinib-resistant cell lines | Modulates imatinib resistance by acting as a ceRNA against miR-16 | CCK-8 assay | siRNAs | RIP assay, Dual-luciferase reporter assay | [123] |
| SNHG5 | Patient samples, imatinib-resistant cell lines | Promotes imatinib resistance through acting as ceRNA against miR-205-5p | MTT assay | siRNAs | RIP assay, Luciferase reporter assay | [125] |
| HOTAIR | Multidrug-resistant patient samples, imatinib-resistant cell lines | Modulates MDR to imatinib resistance through activating PI3K/Akt-dependent pathway | MTT assay, Annexin V/propidium iodide (PI) staining assay | siRNAs | – | [126] |
| MEG3 | Patient samples, imatinib-resistant cell lines | Inhibits imatinib resistance by suppressing miR-21 | CCK-8 assay, Annexin V-FITC/PI Apoptosis Detection Kit | Overexpression | Luciferase reporter assay | [127] |